- Home
- AU vs BIO Comparison
AU vs BIO Comparison
Compare AU & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AU
- BIO
- Stock Information
- Founded
- AU 1944
- BIO 1952
- Country
- AU United States
- BIO United States
- Employees
- AU N/A
- BIO N/A
- Industry
- AU Precious Metals
- BIO Biotechnology: Laboratory Analytical Instruments
- Sector
- AU Basic Materials
- BIO Industrials
- Exchange
- AU Nasdaq
- BIO Nasdaq
- Market Cap
- AU 34.6B
- BIO 8.6B
- IPO Year
- AU 1972
- BIO N/A
- Fundamental
- Price
- AU $69.10
- BIO $307.07
- Analyst Decision
- AU Buy
- BIO Strong Buy
- Analyst Count
- AU 6
- BIO 4
- Target Price
- AU $63.33
- BIO $358.50
- AVG Volume (30 Days)
- AU 3.3M
- BIO 258.8K
- Earning Date
- AU 11-11-2025
- BIO 10-29-2025
- Dividend Yield
- AU 1.36%
- BIO N/A
- EPS Growth
- AU 1303.37
- BIO N/A
- EPS
- AU 3.81
- BIO N/A
- Revenue
- AU $7,649,000,000.00
- BIO $2,557,500,000.00
- Revenue This Year
- AU $65.79
- BIO $2.05
- Revenue Next Year
- AU $8.88
- BIO $2.86
- P/E Ratio
- AU $17.61
- BIO N/A
- Revenue Growth
- AU 54.59
- BIO N/A
- 52 Week Low
- AU $22.45
- BIO $211.43
- 52 Week High
- AU $79.94
- BIO $387.99
- Technical
- Relative Strength Index (RSI)
- AU 52.19
- BIO 47.56
- Support Level
- AU $63.29
- BIO $301.92
- Resistance Level
- AU $69.64
- BIO $343.12
- Average True Range (ATR)
- AU 2.30
- BIO 12.99
- MACD
- AU -0.36
- BIO -3.41
- Stochastic Oscillator
- AU 91.63
- BIO 19.72
About AU AngloGold Ashanti PLC
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
About BIO Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.